

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

Antonio GRILLO-LOPEZ, et al.

Application No. 09/436,348

Filed: November 9, 1999

For: USE OF CHIMERIC ANTI-CD20 AS  
IN VITRO OR IN VIVO PURGING  
AGENT IN PATIENTS RECEIVING  
BMT OR PBSC TRANSPLANT



Group Art Unit: 1641

Examiner: R. Schwadron

RECEIVED

TECH CENTER 1600/2900

REPLY

This Reply is submitted in response to the Office Action mailed June 13, 2000.

Kindly enter the following new claims 7-14 prior to further examination:

7. A method for treating a B cell lymphoma or leukemia in a patient comprising:

- (1) administering to said patient an aggressive therapeutic regimen comprising high dose therapy of one or more of the treatments selected from the group consisting of radioimmunotherapy, whole body irradiation, chemotherapy, cytokine treatment and antibody therapy, wherein said antibody binds to an antigen expressed on the surface of malignant B cells;
- (2) transplanting into said patient bone marrow or peripheral blood stem cells; and
- (3) administering an amount of an antibody specific for a malignant B cell surface antigen, said amount effective to purge malignant B cells.